Business Wire

NY-ORIGINS

Share
Origins and The Estée Lauder Companies Announce Sustainable Packaging Partnership With SABIC and Albéa

Origins, a prestige global skincare brand that delivers high-performance formulas powered by nature and proven by science, and its parent company, The Estée Lauder Companies (ELC), today announced a partnership with global chemical industry leader SABIC and strategic beauty packaging manufacturer Albéa to bring an advanced recycled tube package to market in 2021.

Origins will be the first prestige beauty brand to leverage SABIC’s innovative, advanced recycling technology to produce a tube pack format made from previously difficult to recycle, post-consumer mixed plastics material.

Launching with Origins global best-selling mask, Clear Improvement™ Active Charcoal Mask will be packaged in a tube composed of a circular polymer resin made using SABIC’s revolutionary, certified circular polyethylene and polypropylene advanced recycling technology. As a pioneer in the development of sustainable packaging for beauty brands, Albéa will leverage its expertise in the use of recycled resins to deliver a high-performing tube experience.

Traditional recycling streams for plastics are limited, and plastics can only be recycled a finite amount of times. Advanced recycling returns hard-to-recycle plastics, otherwise destined for incineration or landfill, back to their basic building blocks. Once the plastic has been broken down to its molecular state, it is then used to create high-performance plastics akin to a virgin material. SABIC’s ground-breaking, certified circular polymer, part of its TRUCIRCLE™ portfolio of circular solutions, uses this technology which is capable of continually converting plastics back to the original polymer. Through the use of this innovative recycling technology, Origins, ELC, SABIC and Albéa are helping to drive innovation across the value chain toward the goal of a circular plastic economy.

This strategic partnership aligns with ELC’s sustainable packaging goals, which includes increasing the amount of post-consumer recycled (PCR) material in its packaging by up to 50% by 2025, and will further Origins efforts to ensure that at least 80% of the brand’s packaging by weight is recyclable, refillable, reusable, recycled or recoverable by 2023.

SABIC's certified polymers are based on a mass balance approach. To secure the chain of custody, the value chain parties require an ISCC PLUS certification. This widely recognized international sustainability certification scheme verifies that the mass balance accounting follows predefined and transparent rules. In addition, it provides traceability along the supply chain, from the feedstock to the final product.

“Respect for the well-being of your skin and our planet is ingrained into our brand’s DNA. It guides our actions and is reflected in our Origins offerings which is why we’re excited to partner with SABIC and Albéa to provide our consumers with a safe, high-quality and responsible packaging solution that helps reduce our impact on the environment,” says Francesca Damato, Origins Vice President Global Marketing and Product Development. “Together, we have an exciting opportunity to define how the prestige beauty industry can create sustainable, attractive packaging solutions that please both consumer and the planet. This is a significant first step in the transition towards a circular economy, helping to close the loop on plastic waste.”

“At The Estée Lauder Companies, we approach sustainable design options for our prestige and luxury packaging with a spirit of collaboration. To further our focus on reducing the potential environmental impacts of a package across its lifecycle, we are proud to partner with SABIC and Albéa on Origins industry-first sustainable packaging innovation,” said Sushil Iyer, Vice President, Global Packaging, The Estée Lauder Companies. “Exploring the uses of advanced recycled PCR has incredible potential to help drive the achievement of our sustainable packaging goals, and we are excited to bring this product to market.”

Mark Vester, Circular Economy Leader at SABIC, said “The new Origins packaging is the result of true collaboration and innovation, and another step closer to closing the loop on used plastics. We are committed to collaborating with partners across the value chain to work towards a more sustainable, circular future.”

“Albéa has been at the forefront of sustainable development in packaging for many years and was the first beauty packaging company to commit to making their solutions 100% circular by 2025. This breakthrough with Origins, The Estée Lauder Companies and SABIC is an industry first – paving the way for the use of advanced recycled, post-consumer waste into prestige beauty packaging thanks to an innovative source of high-quality resins,” says Stéphane Barlet, VP of Sales, Albéa Americas. “This co-development also highlights the importance of partnership and audacity across the value-chain, which is crucial to accelerate the transition to recyclable and reusable packaging."

About Origins

Prestige global skincare brand, Origins combines high-quality plant, earth and sea-based ingredients with non-toxic-to-skin alternatives and advanced science to create safe, high-performance products that deliver transformative results. Since inception in 1990, Origins has been committed to respecting the well-being of your skin and our planet – from traveling the world to discover nature’s potent ingredients to endeavoring to make choices that help reduce our impact on the planet. The brand formulates without: parabens, phthalates, propylene glycol, formaldehyde, sodium lauryl sulfate (SLS), mineral oil, petrolatum, paraffin, diathanolamine (DEA), polyethylene beads and animal ingredients (except cruelty free honey & beeswax). Origins is available in 30 countries. For more information, visit www.origins.com ; never stop discovering™ and follow @Origins .

About The Estée Lauder Companies Inc.

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, Tommy Hilfiger, M·A·C, Kiton, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, Tom Ford, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, BECCA, Too Faced and Dr. Jart+.

About SABIC

SABIC is a global leader in diversified chemicals and the company manufacture on a global scale in the Americas, Europe, Middle East and Asia Pacific, making distinctly different kinds of products: chemicals, commodity and high performance plastics, agri-nutrients and metals.

At SABIC, we are working to drive the change needed to close the loop on used plastic. This includes SABIC’s TRUCIRCLE™ portfolio and services which showcases our circular innovations, including our certified circular products which are produced using a feedstock derived from previously difficult to recycle used plastic household packaging. We are collaborating with retailers, recyclers and manufacturers to close the loop and to accelerate the changes we need to make to become a circular global society.

SABIC has more than 33,000 employees worldwide and operates in around 50 countries. Fostering innovation and a spirit of ingenuity, we have 12,540 global patent filings, and have significant research resources with innovation hubs in five key geographies – USA, Europe, Middle East, South Asia and North Asia.

Visit our website for more information: www.sabic.com .

About Albéa

We invent and make responsible packaging – tubes, lipsticks, mascaras, fragrance caps, skincare jars and turnkey solutions – for the beauty, personal care and health markets. Yet we believe there can be no responsible packaging without a responsible company. That’s why we uphold the reputation of our dynamic and prestigious customers; we act for the environment; we support our communities; we invest in technical expertise and world-class equipment for our 32 modern facilities worldwide; and we care for our 12,000 talented people. At Albéa, we protect Beauty. www.albea-group.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye